Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Bredinin
2. Mizoribine 5'-monophosphate
1. 50924-49-7
2. Bredinin
3. He-69
4. Mls000028813
5. 1-((2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-hydroxy-1h-imidazole-4-carboxamide
6. He 69
7. 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-hydroxyimidazole-4-carboxamide
8. Bredinine
9. 5-hydroxy-1-beta-d-ribofuranosyl-1h-imidazole-4-carboxamide
10. 50524-49-7
11. Smr000058473
12. 5-hydroxy-1-beta-d-ribofuranosylimidazole-4-carboxamide
13. 4jr41a10vp
14. 1h-imidazole-4-carboxamide, 5-hydroxy-1-beta-d-ribofuranosyl-
15. Nsc 289637
16. Nsc-289637
17. Ncgc00094087-01
18. Mizoribinum
19. Mizoribina
20. N'-(beta-d-ribofuranosyl)-5-hydroxyimidazole-4-carboxamide
21. Mizoribine [inn:jan]
22. Dsstox_cid_25777
23. Dsstox_rid_81119
24. Dsstox_gsid_45777
25. Mizoribinum [inn-latin]
26. Mizoribina [inn-spanish]
27. Bredinin (tn)
28. 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-hydroxy-1h-imidazole-4-carboxamide
29. Cas-50924-49-7
30. Sr-01000075989
31. Brn 4151713
32. Unii-4jr41a10vp
33. 1h-imidazole-4-carboxamide, 5-hydroxy-1-.beta.-d-ribofuranosyl-
34. 4-carbamoyl-1-beta-d-ribofuranosyl-imidazolium-5-olate
35. Anhydro-4-carbamoyl-5-hydroxy-1-beta-d-ribofuranosyl-imidazolium Hydroxide
36. Mfcd00057221
37. Mizoribine(bredinin)
38. Hs-0046
39. Mizoribine (bredinin)
40. Mizoribine Hydrobromide
41. Mizoribine [mi]
42. Mizoribine [inn]
43. Mizoribine [jan]
44. Opera_id_1558
45. Spectrum2_001559
46. Spectrum3_000739
47. Spectrum4_000220
48. Spectrum5_001671
49. Mizoribine (jp17/inn)
50. M 3047
51. Mizoribine [mart.]
52. Schembl7118
53. Mizoribine [who-dd]
54. Lopac0_000745
55. Bspbio_002298
56. Kbiogr_000859
57. Mls001076272
58. Mls006010038
59. Divk1c_000948
60. Spbio_001438
61. Chembl245019
62. Cid_104762
63. Mizoribine, >=98% (tlc)
64. Dtxsid8045777
65. Bdbm68669
66. Chebi:31858
67. Hms502p10
68. Kbio1_000948
69. Kbio3_001518
70. Ninds_000948
71. Hms2230d04
72. Hms3262e12
73. 50924-49-7 (non-salt)
74. Ex-a2256
75. Zinc3812887
76. Tox21_111242
77. Tox21_500745
78. Ccg-39778
79. Fd9057
80. S1384
81. Akos015994615
82. Tox21_111242_1
83. Ac-5266
84. Bcp9000933
85. Cs-1823
86. Db12617
87. Lp00745
88. Sdccgsbi-0050723.p004
89. Idi1_000948
90. Smp1_000195
91. Ncgc00094087-02
92. Ncgc00094087-03
93. Ncgc00094087-04
94. Ncgc00094087-05
95. Ncgc00261430-01
96. Hy-17470
97. Bcp0726000318
98. Sbi-0050723.p003
99. Eu-0100745
100. M2399
101. A16794
102. D01392
103. Ab00053323_12
104. Ab00053323_13
105. 924m497
106. J-700185
107. Q6884708
108. Sr-01000075989-1
109. Sr-01000075989-4
110. 1-(beta-d-ribofuranosyl)-5-hydroxyimidazole-4-carboxamide
111. 4-carbamoyl-1-(beta-d-ribofuranosyl)-5-oxylatoimidazolium
112. 5-hydroxy-1-b-d-ribofuranosyl-1h-imidazole-4-carboxamide
113. 1h-imidazole-4-carboxamide, 5-hydroxy-1-b-d-ribofuranosyl-
114. 5-hydroxy-1-.beta.-d-ribofuranosylimidazole-4-carboxamide
115. 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)-2-oxolanyl]-5-hydroxy-4-imidazolecarboxamide
116. 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-5-hydroxy-imidazole-4-carboxamide
117. 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-methylol-tetrahydrofuran-2-yl]-5-hydroxy-imidazole-4-carboxamide
118. 1-[(2r,3r,4s,5r)-5-(hydroxymethyl)-3,4-bis(oxidanyl)oxolan-2-yl]-5-oxidanyl-imidazole-4-carboxamide
| Molecular Weight | 259.22 g/mol |
|---|---|
| Molecular Formula | C9H13N3O6 |
| XLogP3 | -1.9 |
| Hydrogen Bond Donor Count | 5 |
| Hydrogen Bond Acceptor Count | 7 |
| Rotatable Bond Count | 3 |
| Exact Mass | 259.08043514 g/mol |
| Monoisotopic Mass | 259.08043514 g/mol |
| Topological Polar Surface Area | 151 Ų |
| Heavy Atom Count | 18 |
| Formal Charge | 0 |
| Complexity | 329 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 4 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Anti-Inflammatory Agents, Non-Steroidal
Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. (See all compounds classified as Anti-Inflammatory Agents, Non-Steroidal.)
Antibiotics, Antineoplastic
Chemical substances, produced by microorganisms, inhibiting or preventing the proliferation of neoplasms. (See all compounds classified as Antibiotics, Antineoplastic.)
Antimalarials
Agents used in the treatment of malaria. They are usually classified on the basis of their action against plasmodia at different stages in their life cycle in the human. (From AMA, Drug Evaluations Annual, 1992, p1585) (See all compounds classified as Antimalarials.)
Anti-Bacterial Agents
Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)
Immunosuppressive Agents
Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. (See all compounds classified as Immunosuppressive Agents.)
Enzyme Inhibitors
Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)
API SUPPLIERS
Registration Number : 221MF10012
Registrant's Address : 47, Jeyakdanji-ro, Hyangnam-eup, Hwaseong-si, Gyeonggi-do, Republic of Korea
Initial Date of Registration : 2009-01-13
Latest Date of Registration : --
Registration Number : 221MF10052
Registrant's Address : 2-10-1 Shinseicho, Choshi City, Chiba Prefecture
Initial Date of Registration : 2009-03-16
Latest Date of Registration : --
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Market Place
APIs
Reply
19 Feb 2016
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Mizoribine manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Mizoribine, including repackagers and relabelers. The FDA regulates Mizoribine manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Mizoribine API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Mizoribine supplier is an individual or a company that provides Mizoribine active pharmaceutical ingredient (API) or Mizoribine finished formulations upon request. The Mizoribine suppliers may include Mizoribine API manufacturers, exporters, distributors and traders.
click here to find a list of Mizoribine suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Mizoribine Drug Master File in Japan (Mizoribine JDMF) empowers Mizoribine API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Mizoribine JDMF during the approval evaluation for pharmaceutical products. At the time of Mizoribine JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Mizoribine suppliers with JDMF on PharmaCompass.
Mizoribine Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Mizoribine GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Mizoribine GMP manufacturer or Mizoribine GMP API supplier for your needs.
A Mizoribine CoA (Certificate of Analysis) is a formal document that attests to Mizoribine's compliance with Mizoribine specifications and serves as a tool for batch-level quality control.
Mizoribine CoA mostly includes findings from lab analyses of a specific batch. For each Mizoribine CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Mizoribine may be tested according to a variety of international standards, such as European Pharmacopoeia (Mizoribine EP), Mizoribine JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Mizoribine USP).
LOOKING FOR A SUPPLIER?
Comment (3)
